Literature DB >> 19010792

Rescue of a severe mouse model for spinal muscular atrophy by U7 snRNA-mediated splicing modulation.

Kathrin Meyer1, Julien Marquis, Judith Trüb, Rachel Nlend Nlend, Sonia Verp, Marc-David Ruepp, Hans Imboden, Isabelle Barde, Didier Trono, Daniel Schümperli.   

Abstract

In spinal muscular atrophy (SMA), the leading genetic cause of early childhood death, the survival motor neuron 1 gene (SMN1) is deleted or inactivated. The nearly identical SMN2 gene has a silent mutation that impairs the utilization of exon 7 and the production of functional protein. It has been hypothesized that therapies boosting SMN2 exon 7 inclusion might prevent or cure SMA. Exon 7 inclusion can be stimulated in cell culture by oligonucleotides or intracellularly expressed RNAs, but evidence for an in vivo improvement of SMA symptoms is lacking. Here, we unambiguously confirm the above hypothesis by showing that a bifunctional U7 snRNA that stimulates exon 7 inclusion, when introduced by germline transgenesis, can efficiently complement the most severe mouse SMA model. These results are significant for the development of a somatic SMA therapy, but may also provide new means to study pathophysiological aspects of this devastating disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19010792     DOI: 10.1093/hmg/ddn382

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  48 in total

Review 1.  Regulation of alternative splicing by short non-coding nuclear RNAs.

Authors:  Amit Khanna; Stefan Stamm
Journal:  RNA Biol       Date:  2010-07-01       Impact factor: 4.652

Review 2.  Developments in RNA splicing and disease.

Authors:  Michael G Poulos; Ranjan Batra; Konstantinos Charizanis; Maurice S Swanson
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-01-01       Impact factor: 10.005

Review 3.  The pathogenicity of splicing defects: mechanistic insights into pre-mRNA processing inform novel therapeutic approaches.

Authors:  Elisabeth Daguenet; Gwendal Dujardin; Juan Valcárcel
Journal:  EMBO Rep       Date:  2015-11-13       Impact factor: 8.807

4.  Antisense oligonucleotides and spinal muscular atrophy: skipping along.

Authors:  Arthur H M Burghes; Vicki L McGovern
Journal:  Genes Dev       Date:  2010-08-01       Impact factor: 11.361

5.  Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model.

Authors:  Yimin Hua; Kentaro Sahashi; Gene Hung; Frank Rigo; Marco A Passini; C Frank Bennett; Adrian R Krainer
Journal:  Genes Dev       Date:  2010-07-12       Impact factor: 11.361

6.  Temporal requirement for high SMN expression in SMA mice.

Authors:  Thanh T Le; Vicki L McGovern; Isaac E Alwine; Xueyong Wang; Aurelie Massoni-Laporte; Mark M Rich; Arthur H M Burghes
Journal:  Hum Mol Genet       Date:  2011-06-13       Impact factor: 6.150

Review 7.  Mechanistic principles of antisense targets for the treatment of spinal muscular atrophy.

Authors:  Natalia N Singh; Brian M Lee; Christine J DiDonato; Ravindra N Singh
Journal:  Future Med Chem       Date:  2015-09-18       Impact factor: 3.808

8.  Trans-splicing-mediated improvement in a severe mouse model of spinal muscular atrophy.

Authors:  Tristan H Coady; Christian L Lorson
Journal:  J Neurosci       Date:  2010-01-06       Impact factor: 6.167

9.  Restoration of full-length SMN promoted by adenoviral vectors expressing RNA antisense oligonucleotides embedded in U7 snRNAs.

Authors:  Till Geib; Klemens J Hertel
Journal:  PLoS One       Date:  2009-12-08       Impact factor: 3.240

Review 10.  SMN-inducing compounds for the treatment of spinal muscular atrophy.

Authors:  Monique A Lorson; Christian L Lorson
Journal:  Future Med Chem       Date:  2012-10       Impact factor: 3.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.